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TryptaseChronic obstructive pulmonary disease (COPD) is a multicomponent disease characterized by emphysema
and/or chronic bronchitis. The aim of this study was to investigate the effect of cigarette smoke exposure
on mast cells and mast cell function in vitro and in vivo in order to get further insight in the role of mast
cells in the pathogenesis of emphysema. Cigarette smoke conditioned medium (CSM) induced the expression
of mast cell tryptase (MMCP-6) in primary cultured mast cells. This tryptase expression was caused by the
CSM-stimulated production of TGF-β in culture and neutralization of TGF-β suppressed the CSM-induced ex-
pression of tryptase inmast cells. An increase inmast cell tryptase expressionwas also found in an experimental
model for emphysema. Exposure of mice to cigarette smoke increased the number of mast cells in the airways
and the expression ofmast cell tryptase. In accordancewith the in vitroﬁndings, TGF-β in bronchoalveolar lavage
ﬂuid of smoke-exposed animals was signiﬁcantly increased. Our study indicates that mast cells may be a source
of TGF-β production after cigarette smoke exposure and that in turn TGF-βmay change the tryptase expression
in mast cells.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Chronic obstructive pulmonary disease (COPD) is a major and
increasing global health problem [1]. COPD is characterized by a
complex interaction between inﬂammatory and structural cells, all of
which have the capacity to release multiple inﬂammatory mediators
[2]. Cigarette smoke (CS) is the major player in the pathogenesis of
COPD [2]. Exposure to CS activates an inﬂammatory cascade in the
airways resulting in the production of a number of potent cytokines
and chemokines with accompanying damage to the lung epithelium,
increased permeability and recruitment ofmacrophages andneutrophils
[3].
Mast cells normally reside close to epithelia, blood vessels, nerves,
near smooth muscle cells and mucus-producing glands [4]. Mast cells
at these locations will be exposed to inhaled, environmental chal-
lenges. Since mast cell activation results in the coordinated release
of pro-inﬂammatorymediators into the surrounding tissue, activation
of this cell type following exposure to environmental challenges may
result in chronic inﬂammatory pathology [5]. Notably, in COPD
patients an accumulation of mast cells in the airways has been
observed [6]., Utrecht Institute for Pharma-
ty, P.O. BOX 80082, 3584 CG
l rights reserved.Mast cell proteinases (MCPs) are serine proteases, and eleven
mouse MCPs have been described to date [7]. Interestingly, Huang
et al. suggested that tryptase facilitates the inﬂux of neutrophils into
inﬂammation sites and injection of mMCP-6 increases the number
of neutrophils in the peritoneal cavity [8]. In an in vitro model,
mMCP-6 induced mRNA expression of IL-8 by cultured endothelial
cells [8]. There is an intimate relationship between tryptase levels
in airways and chronic degradation in airway function [9]. It
is therefore not surprising that, in several disease states that are char-
acterized by remodeled airways (such as COPD and allergic asthma),
increased mast cell activation and elevated levels of secreted protein-
ases are observed [10]. Earlier studies demonstrated elevated hista-
mine and tryptase levels in bronchoalveolar lavage ﬂuid of smokers
[11]. Exposure of RBL-2H3 (rat basophilic leukemia cell line) with
tobacco-derived materials induces overproduction of proteinases
[12], but attenuates degranulation via the release of NO [13]. More-
over, it has been shown that cigarette smoke exposure exacerbates
mouse airway inﬂammation and tissue remodeling via TGF-β/Smad
proteins expressed by activated mast cells [14]. We have demonstrated
in previous studies that CSM induces chemokine release and suppresses
degranulation of mast cells [15,16].
In this study, we investigated whether cigarette smoke changed
mast cell properties in murine airways. We show that cigarette
smoke induces increased expression of mast cell tryptase, which
may be related to a smoke-induced increase in TGF-β expression by
mast cells.
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2.1. Reagents
Recombinant mouse IL-3 and SCF (Stem cell factor) were pur-
chased from Peprotech (Tebu Bio, Heerhugowaard, The Netherlands).
LPS (Escherichia coli 055.B5)was purchased fromSigma (Sigma-Aldrich,
Zwijndrecht, The Netherlands). RPMI 1640, Tyrode's buffer, fetal calf
serum, nonessential amino acids were purchased from GibCo BRL
Life Technologies (GIBCO-BRL Invitrogen Corporation, Carlsbad, CA,
USA). Penicillin, streptomycin, L-glutamine, sodium pyruvate, and
2-mercaptoethanol were obtained from Sigma-Aldrich.
2.2. Production of cigarette smoke medium (CSM)
Cigarette smoke-conditioned medium (CSM) was produced fol-
lowing the method as described before [17]. CSM was generated by
the burning of commercially available from the reference cigarettes
2R4F (University of Kentucky, Lexington, Kentucky), using the TE-
10z smoking machine (Teague Enterprises, Davis, CA, USA), which is
programmed to smoke cigarettes according to the Federal Trade Com-
mission protocol (35-ml puff volume drawn for 2 s, once per minute).
Brieﬂy, this machine was used to direct main- and side-stream smoke
from one cigarette through a 5-ml culture medium (RPMI without
phenol red). Hereafter, absorbance was measured spectrophotometri-
cally, and the media were standardized to the absorbance at 320 nm.
The pH of the resultant extract was titrated to pH 7.4 and diluted with
medium. This concentration (optical density [OD]=4.0) was serially
diluted with untreated media to 0.75%, 1.5%, and 3% OD and used in
the indicated experiments. Except for the dose–response and viability
test, CSM at a concentration of 1.5% was selected for use in all
experiments.
2.3. Mouse bone marrow-cultured mast cells (BMMC)
Bone marrow-derived mast cells were generated from male BALB/
cBy mice as described before [18]. Brieﬂy, mice were sacriﬁced, and
intact femurs were removed. Sterile, endotoxin-free medium was
ﬂushed repeatedly through the bone shaft using a needle and syringe.
The suspension of BM cells was centrifuged at 320 g for 10 min and
cultured at a concentration of 0.5×106 nucleated cells/ml in RPMI
1640 with 10% FCS (Sigma-Aldrich) 100 units/ml penicillin, 100 μg/ml
streptomycin (Life Technology, Breda, The Netherlands), 10 μg/ml
gentamycine, 2 mM L-glutamine, and 0.1 mM nonessential amino
acids (referred to as enriched medium) and a combination of IL-3
(5 ng/ml) and SCF (50 ng/ml) for 3 weeks at 37 °C in a humidiﬁed
atmosphere with 5% CO2. Non-adherent cells were transferred to fresh
medium at least once a week. After 3–4 weeks when a mast cell purity
of >95% was achieved, as assessed by toluidine blue staining, the cells
were used for the experiments.
2.4. Treatment of BMMC
To study the effects of CSM onmorphology and tryptase expression
bone marrow cells were cultured in medium. At week 2 or 3 cultures
were co-incubated with CSM for 6 days (maximum effects) daily
added to the culture medium or for 24 h only CSM (1.5%) or LPS
(100 ng/ml). The morphology of cells and expression of tryptase were
determined by histochemical staining and Western blot analysis.
2.5. Neutralizing TGF-β in in vitro BMMC culture
Using neutralizing antibodies directed against TGF-β, we investi-
gated the role of this cytokine in tryptase expression induced by
CSM. BMMC were incubated with 10 μg/ml anti-TGF-β, or isotype
control IgG antibodies for 30–60 min at 37 °C followed by incubationwith CSM for 24 h in presence of the antibodies. Thereafter, cell
lysates were subjected to SDS-PAGE and immunoblotting for analysis
of mast cell tryptase expression.
2.6. Measurement of cytokines
Brieﬂy, approximately 1×106 cells for each experimental condition
were resuspended in culture medium and incubated with 1 μg/ml anti-
DNP IgE. After that, cells were washed and resuspended. Cells were
aliquoted in 96 well plates (1×106 cells/ml) and activated with indi-
cated concentrations of DNP-Ova for 16 h. TGF-β concentrations in
supernatants of cells were quantitated using ELISA kits (Invitrogen
and eBioscience), according to the manufacturer's instruction.
2.7. Analysis of tryptase expression by Western blotting
Treated cells were washed once in PBS and lysed in ice-cold
buffer containing 50 mM Tris (pH 8.0), 110 mM NaCl, 5 mM EDTA,
1% Triton X-100, and PMSF (100 mg/mL). Protein concentrations
were determined by BCA protein assay kit (Pierce, Perbio Science,
Erembodegem-Aalst, Belgium). Whole-cell lysates (50 mg) were
boiled for 5 min in equal volumes of loading buffer (125 mM Tris–HCl,
pH 6.8, 4% SDS, 20% glycerol) and 10% 2-mercaptoethanol and loaded
per lane on an 8 to 16% Tris-glycine gradient gel. Proteinswere separated
electrophoretically and transferred onto PVDF membranes (Bio-Rad
Laboratories, B.V., Veenendaal, The Netherlands) using the Novex Xcell
Mini-Gel system (Invitrogen, Breda, The Netherlands). For immunoblot-
ting, membranes were blocked with PBS containing 5% dry milk for 1 h.
Primary antibodies formouse anti-tryptase (mMCP-6; cat no: sc:32889),
and goat anti-actin antibodies (Santa Cruz) were applied at appropriate
dilutions for 2 h. After being washed two times in TBS containing 0.05%
Tween-20 (T-TBS), appropriate peroxidase-conjugated secondary anti-
bodies were applied at 1:10,000 dilution for 1 h. Blots were washed in
T-TBS two times over 30 min, incubated in commercial enhanced chemi-
luminescence reagents (ECL; Amersham, Buckinghamshire, UK), and
exposed to photographic ﬁlm. Filmswere scanned on a GS710 calibrated
imaging densitometer and analyzed by means of Quantity One v. 4.0.3
software from Bio-Rad.
2.8. Animals
Nine to 14 week-old female A/J (Charles River Laboratories, The
Netherlands) and BALB/c mice (Taconic Europe A/S, Denmark),
were housed under controlled conditions in standard laboratory
cages. They were provided free access to water and food. All in vivo
experimental protocols were approved by the local Ethics Committee
and were performed under strict governmental and international
guidelines on animal experimentation in The Netherlands. BALB/c
animals were handled in conformity with standards established by
Council of Europe ETS123 AppA, Swedish legislation and AstraZeneca
Global Internal Standards.
2.9. Cigarette smoke exposure
Female A/J mice were divided into three groups. Group 1 was
exposed for 1 week to cigarette smoke, group 2 for 1 month and
group 3 for 5 months. Control animals were exposed to room air. The
micewere exposed in whole-body chambers to air (sham) or to diluted
mainstream cigarette smoke from the reference cigarettes 2R4F
(University of Kentucky, Lexington, Kentucky) using a smoking appara-
tus. Exposures were conducted 4 h/day (with a 30/60-minute fresh air
break after each hour of exposure), 5 days/week for 20 weeks to a target
cigarette smoke concentration of 750 μg total particulate matter/l
(TPM/l). This TPM concentration was reached after an adaptation
period of 1 week, starting with a TPM concentration of 125 μg TPM/l.
The mass concentration of cigarette smoke TPM was determined by
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ﬁced 16–24 h after the last air or smoke exposure, or after the smoke-
free period of 8 weeks. For the short smoking exposure protocol,
BALB/c mice were exposed to cigarette smoke using a whole body
smoke exposure unit SIU48 (PromechLab AB, Vintrie, Sweden). Up to
64 mice were placed in a sealed exposure chamber, divided into sepa-
rate chambers and exposed to mainstream tobacco smoke or room air
(control mice). Smoke was generated from 1R3F research cigarettes
(Tobacco and Health Research Institute, University of Kentucky) with
ﬁlters removed. Smoke was drawn into the box with a vacuum ﬂow
that was aligned to 10 puffs per cigarette. Air was drawn into the box
after each puff, and the control unit automatically cycled the opening
and closing of air and smoke inlets (5 seconds air and 10 seconds
smoke). Side stream smoke was removed via exhaust. Animals were
exposed to 10 cigarettes, twice daily, for 4, 7 or 9 days. There was a
5 h interval between the exposures. The SIU48 allows for monitoring
of smoke input in real time to ensure consistency between exposures.
Termination and analysis were carried out in each case 16 h after the
last smoke exposure.2.10. Determination of TGF-β in bronchoalveolar lavage ﬂuid (BALF)
Mice were exposed to 2 exposures/day during 3 days as described
before [19]. Mice were sacriﬁced by an i.p. injection with an overdose
of pentobarbital (Nembutal™, Ceva Santé Animale, Naaldwijk, The
Netherlands) 24 h after the last smoke exposure and BAL was collected.
The lungs were lavaged using 1 aliquot (1 ml) of saline solution (NaCl
0.9%) containing a mixture of protease inhibitors (Complete Mini,
Roche Applied Science) at 37 °C. The BALF was centrifuged at 4 °C
(400 g, 5 min) and the supernatant was immediately stored at−20 °C
until the TGF-βmeasurements.2.11. Immunohistology of tryptase
Prior to the application of primary antibodies, tissue sections
(5 μM) were deparafﬁnized, rehydrated, and subjected to antigen
retrieval. For antigen retrieval, slides were immersed in sodium
citrate buffer, pH 6.0, in an 86 °C water bath for 15 min. After being
rinsed with water, followed by incubation in PBS for 5 min, tissue
was blocked with normal goat serum (Vector, Peterborough, UK) for
20 min. Tissue was incubated with 150 μl of rabbit anti-mouse
tryptase (mouse mast cell protease-6) (Santa Cruz, Tebu-Bio, The
Netherlands) primary antibody in predetermined optimal dilutions
for 1 h at room temperature, washed in PBS, then incubated for
30 min in 500 μl of goat anti-rabbit biotinylated secondary antibody
(DAKO, Denmark) diluted 1:150 in PBS. Slides were thereafter
washed in PBS and incubated in freshly complexed avidin–biotin
alkaline phosphatase ABC reagent (Vectastain ABC kit; Vector) for
20 min. After a ﬁnal series of washes in PBS, 200 μl of fast red
(1 mg/ml) (Sigma-Aldrich, The Netherlands) substrate was applied
for 25 min. This reaction was stopped by rinsing with distilled
water, and the tissue was subsequently counterstained with Gill's II
hematoxylin (Fisher Scientiﬁc, Fair Lawn, NJ) and mounted with
Crystal/Mount (Biomeda, Foster City, CA).2.12. Statistical analysis
Experimental results are expressed as mean±S.E.M. Results were
tested statistically by an unpaired two-tailed Student's t-test or one-
way ANOVA, followed by Newman–Keuls test for comparing all
pairs of groups. Analyses were performed by using GraphPad Prism
(version 2.01). Results were considered statistically signiﬁcant when
pb0.05.3. Results
3.1. CSM modulates mast cell tryptase expression
Bone marrow-derived cultured mast cells were used as a model
for mucosal mast cells to investigate the effects of exposure to CSM.
Exposure of mast cells for a period of 6 days induced the expression
of mouse mast cell protease-6 (mMCP-6), a mast cell-speciﬁc tryptase,
as detected by IHC on cytospins. In Fig. 1A, control cells are shown
and Fig. 1B, BMMC cocultured with CSM. The number of tryptase-
positive cells was signiﬁcantly increased when BMMC were cultured
in the presence of CSM (Fig. 1C). The increased expression of mMCP-6
in BMMC was conﬁrmed by Western blotting (Fig. 1D).
3.2. CSM induces TGF-β expression in cultured mast cells
TGF-β has been described to modulate mast cell development,
while activated mast cells can produce TGF-β. In the next experiment,
we investigated if exposure to CSM induced TGF-β expression in
BMMCs. Fig. 2A shows that coculture of BMMCs with CSM for 24 h
induced a signiﬁcant production of TGF-β.
3.3. Neutralizing of TGF-β suppresses CSM-induced tryptase expression
in BMMC
BMMC were pretreated with TGF-β neutralizing antibody for 30–
60min and then exposed with CSM for 24 h. Incubation of cells with a
neutralizing TGF-β antibody, greatly suppressed the CSM-induced
upregulation of tryptase (Fig. 2B).
3.4. Cigarette smoke exposure increases the number of tryptase-positive
mast cells in lungs
Knowing that inﬂammatory stimuli can modulate tissue mast cell
composition, we next examined the lung mast cell phenotype in the
context of lung emphysema. For these experiments, lung emphysema
was induced in AJ/C mice by whole body exposure to cigarette smoke
for 7 days, one month and 5 months.
For characterization of airway mast cells, sections were scored at
high magniﬁcation counting the toluidine stained granular cells
(Fig. 3A). In the cigarette smoke-exposed animals the number of mast
cells was also increased as quantiﬁed by immunohistochemical staining
with anti-tryptase (mMCP-6), The tryptase expression increased with
duration of time of exposure to cigarette smoke (Fig. 3: C, control; D,
1 week; E, 1 month; F, 5 months exposure). Panel 3B shows staining
with the secondary Ab only, illustrating the speciﬁcity of the tryptase
staining. The number of mast cells as determined by toluidine staining
and tryptase expression was signiﬁcantly increased as early as 1 week
after the start of cigarette smoke exposure (Fig. 3 J+H).
3.5. Smoke exposure increased TGF-β in BAL ﬂuid of mice
We measured the concentration of TGF-β in BAL of smoke-exposed
mice. As depicted in Fig. 4, after one week of cigarette smoke exposure
increased concentrations of TGF-βwere found in BAL ﬂuid as compared
to control mice (panel A). Also TGF-β expression in lung tissue was
enhanced after cigarette smoke exposure (panel C) as compared to
lung tissue of controls (panel B).
4. Discussion
We studied the effect of cigarette smoke on the tryptase (mMCP-6)
expression mast cells and showed that CSM induced the expression of
tryptase in cultured primary mast cells. The increased expression of
mMCP-6 was abolished by neutralizing CSM-induced TGF-β produc-


















































Fig. 1. CSMup-regulates expression of tryptase bymast cells. Panels A and B. BMMCwere cultured for in presence of CSM (1.5%) for 6 days. Intracellular tryptasewas detectedwith IHC in
control cells (panel A) and CSM cocultured BMMC (panel B). Panel C, quantitation of the number of tryptase-positivemast cells in the immunostained cytospins. Representative results are
selected from 3 independent experiments (original magniﬁcation×400). Each slide was normalized by counting 100 cells from 4 parts of the slide. The numbers of counted cells are plot-

































Fig. 2. CS exposure increased the release of TGF-β and suppression of tryptase expression by mast cells. Panel A. BMMCwere cultured in presence of CSM (1.5%) for 24 h. The release
of TGF-β was determined in cell supernatants by ELISA methods. Data shown are mean±SE of three independent experiments (**pb0.01). Panel B. TGF-β neutralizing antibodies
suppress CSM-induced tryptase expression. BMMCwere incubated with TGF-β neutralizing antibodies for 30–60 min and then treated with CSM for 24 h. After that, cells were lysed
and cell lysates were subjected to Western blotting with anti TGF-β and GAPDH (Stress Gen, Canada) as a housekeeping protein, on the same samples. Densitometric analysis of
three immunoblots from 3 independent experiments is shown in the lower panel (mean±SEM). *pb0.05 compared to control; # not signiﬁcant compared to control.





















































Fig. 3. Cigarette smoke exposure modulates mast cell number and tryptase expression in murine lungs. Panel A. Toluidine blue staining of sections of lungs (arrows point at some
toluidine blue-positive granular cells present in the tissue section). Panel B. Staining control for tryptase IHC. Tissue was stained with a secondary Ab only. Panels C–F. Represen-
tative lung sections stained with anti-tryptase (mMCP-6) antibody. Lung tissue from control mice (C) or mice exposed for 1 week with cigarette smoke (D) or mice exposed for
1 month with cigarette smoke (E) and mice exposed for 5 months with cigarette smoke (F). Results are representative of 3 independent experiments (original magniﬁcation×200).
Arrows indicate tryptase-positive mast cells. Panels J and H represent quantiﬁcation of toluidine blue-positive (J) and tryptase-positive cells (H). Mast cells on 4 slides from 4
independent experiments were counted (≥100 cells/slide). The asterisks represent signiﬁcant differences compared with control alone (**pb0.01 and ***pb0.001).














Fig. 4. CS exposure increased the release of TGF-β in BAL ﬂuid and increases TGF-β-positive mast cells in lungs. Panel A, after harvesting of BAL ﬂuid from control and cigarette
smoke-exposed BALB/c mice (exposure for 1 week), TGF-β was determined by ELISA. Data are presented as mean±SE (n=5 mice/group), ***pb0.001 compared to control.
Panel B and C, representative lung sections of BALB/c after 1 week of cigarette-smoke exposure. The sections were stained with anti-TGF-β mAb as described in Materials and
methods section. Arrows indicate TGF-β positive cells.
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which was also accompanied with increased tissue expression and
BAL levels of TGF-β. Mast cells are playing a critical role in pathogenesis
of allergic [20,21] and non-allergic disorders [24–24]. Studies are accu-
mulating on the distribution, type of mast cells in lungs and tissues of
smokers and COPD patients and their potential role in pathogenesis of
disease. Mast cells normally reside close to epithelia, blood vessels,
nerves, smooth muscle cells, and mucus-producing glands [25]. Re-
cently, it has been demonstrated that the numbers of mast cells were
signiﬁcantly increased in sputum of smokers compared to ex-smokers
[26]. The role of tryptic enzymes has been suggested in the pathogene-
sis of COPD [27,28]. However, the source of tryptase in COPD is unclear.
Tryptase activity is markedly increased in sputum and plasma of severe
COPD patients and suggested that this enhanced activity may contrib-
ute to the pathogenesis of COPD [29]. Kim et al. described that cigarette
smoke exacerbates the development of allergic asthma by mast cell
activation through TGF-β/Smad signaling [14]. Cigarette smoke ele-
vated the numbers of mast cells in BAL cells and lung tissues of OVA/S
mice, although both studies differed in various factors such as smoke
exposed periods and allergen challenge. TGF-β up-regulate the expres-
sion of tryptase (mMCP-6 and -7) in mouse mast cell progenitors [30].
We show that the cigarette smoke-induced increase in TGF-β indeed
is responsible for the increased expression of mast cell tryptase
(mMCP-6). The major sources of proteases within the lung are inﬂam-
matory cells, such as neutrophils,mast cells, macrophages, and lympho-
cytes [31]. Several studies have highlighted the potential role of mast
cells in mediating extracellular matrix degradation through the release
of mMCPs. Mast cell tryptase and chymase activate the precursors
of MMP-2 (gelatinase A) [32] and MMP-9 (gelatinase B) [33]. Interest-
ingly, recombinant mMCP-6 can selectively induce large numbers of
neutrophils to extravasate into the peritoneal cavity of various mouse
strains [8] and mMCP-6 (but not mMCP-7) was found essential for the
development of experimental colitis. The mast cell-restricted tryptase
controlled the inﬂammation and damage to the colon's ECM [34].
mMCP-6 induces cultured endothelial cells to selectively increase
their expression of the neutrophil chemoattractant IL-8 [8]. Thus up-
regulation of tryptase by CSM may account for a role of mast cells in
the potentiation of neutrophil recruitment into the airways. In agree-
ment with our observations, Small-Howard et al. reported that chronic
exposure to cigarette smoke up-regulates tryptase levels in a rat mast
cell lines at both the protein and the mRNA level [35].
Taken together our study shows that cigarette smoke causes an
increase in the mast cell population and a change in phenotype of
mast cells. Cigarette smoke induced the release of TGF-β from mast
cells which was shown to be responsible for the induction of tryptase
expression in mast cells. Tryptase could in turn play a role inrecruitment of neutrophils [36]. To what respect these effects contrib-
ute to pathological airway remodeling in lung emphysema remains to
be elucidated in future research.
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